Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA

Health CarePharmaceuticals and Biotechnology
  • Price (CHF)1.45
  • Today's Change-0.08 / -5.23%
  • Shares traded2.13k
  • 1 Year change-42.23%
  • Beta1.2077
Data delayed at least 15 minutes, as of Jul 01 2022 16:30 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

  • Revenue in CHF (TTM)5.77m
  • Net income in CHF-14.91m
  • Incorporated2002
  • Employees25.00
  • Location
    Newron Pharmaceuticals SpAvia Ludovico Ariosto 21BRESSO 20091ItalyITA
  • Phone+39 26103461
  • Fax+39 261034654
  • Websitehttps://www.newron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
BioMaxima SA31.43m6.00m22.55m--3.771.963.530.71756.496.4933.1112.492.345.4116.57--44.678.7454.4413.5639.2540.4719.107.632.55--0.1194--31.6124.1539.0957.0148.53--
ViroGates A/S1.18m-2.20m23.00m14.00--11.53--19.47-5.21-5.212.794.250.37221.304.19---69.36-46.55-80.77-52.0374.62-14.35-186.34-349.763.78-115.200.00--43.0015.745.73------
RLS Global AB80.52k-944.12k23.06m----16.76--286.38-0.1515-0.15150.01290.22070.0364--0.7195---42.64-48.17-52.19-56.91--34.51-1,172.51-1,175.261.40--0.00---68.04-25.6849.96------
Bioceltix SA0.00-1.12m24.09m----24.79-----1.60-1.600.001.390.0022.40-----57.62---70.78----------2.81-286.950.095---100.00---87.23------
genOway SA12.46m-405.67k27.34m121.00--1.7523.222.19-0.0427-0.04271.661.720.4479-0.03092.46105,461.90-1.461.57-1.982.51100.2890.86-3.262.712.03-3.000.40070.0016.486.3333.69--94.79--
Newron Pharmaceuticals SpA5.77m-14.91m27.41m25.00--8.81--4.75-0.8358-0.83580.32320.17430.1133--3.64230,692.60-29.31-25.64-32.70-28.1797.9786.47-258.61-216.08---4.640.9327--9.594.0029.04---22.60--
Abliva AB14.11k-11.59m27.49m8.00--6.65--1,949.04-0.305-0.3050.00040.04870.002--0.125918,875.00-168.77-67.30-222.48-79.05-----82,165.56-76,095.50---163.760.00---30.0960.91-105.86---43.06--
Nordic Nanovector ASA0.00-43.12m28.34m40.00--0.9104-----4.46-4.460.002.770.00----0.00-99.19-69.82-127.27-88.28-------636,940.80---229.600.00-------5.81---29.60--
Vo2 Cap Holding AB (publ)35.78m-1.18m28.54m--361.681.91793.500.79770.01720.017211.473.262.46--14.98---8.12-31.87-11.69-57.9519.6126.64-3.30-19.29---23.510.1984--46,310.78185.46-246.86------
Adocia SA1.45m-22.78m28.73m112.00------19.87-3.22-3.220.2046-1.910.0384--13.9512,892.86-60.50-23.00-111.70-30.70-----1,575.76-92.050.9079-5.721.67--71.70-42.252.44---46.29--
Kancera AB0.00-4.54m28.95m7.00--2.80-----0.8435-0.84350.001.970.00-------48.53-68.51-54.84-86.40--92.88---5,941.59---99.430.00---100.00---12.80------
Alligator Bioscience AB1.65m-14.21m30.00m48.00--1.35--18.16-1.13-1.130.11261.080.0727--7.13384,391.30-62.49-33.26-73.25-36.20-----860.03-672.07----0.0859--197.40-25.981.09---58.36--
Arctic Bioscience AS-9.70bn-9.70bn31.92m--------------------------------------------------4.97---88.48------
Vivesto AB2.44m-11.02m32.17m19.00--0.4831--13.17-0.2496-0.24960.05631.320.03431.444.941,188,864.00-15.47---18.08---68.59---451.04--6.11-30.480.0116--------------
Farmsintez PAO7.61m-12.11m32.48m119.00--3.53--4.27-2.32-2.321.461.150.25215.241.63---40.12-21.01-95.59-28.7736.7438.24-159.14-175.640.1712-5.550.6723--17.94-7.90-32.91---61.63--
Sensorion SA0.00-15.16m32.50m39.00--0.7367-----0.1899-0.18990.000.55110.00----0.00-23.84-35.94-26.99-47.78-----------133.920.0846-------68.60--14.33--
Data as of Jul 01 2022. Currency figures normalised to Newron Pharmaceuticals SpA's reporting currency: Swiss Franc CHF

Institutional shareholders

3.66%Per cent of shares held by top holders
HolderShares% Held
Credit Suisse Asset Management (Schweiz) AGas of 31 May 2022196.58k1.10%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020173.17k0.97%
UBS Asset Management Switzerland AGas of 31 May 2022146.25k0.82%
TOBAM SASas of 31 Dec 202051.25k0.29%
Pictet Asset Management SAas of 28 Feb 202229.73k0.17%
BlackRock Asset Management Schweiz AGas of 02 Jun 202225.77k0.14%
Lombard Odier Asset Management (Switzerland) SAas of 29 Apr 202215.24k0.09%
DWS CH AGas of 30 Nov 20206.25k0.04%
LLB Asset Management AGas of 30 Apr 20225.20k0.03%
Migros Bank AGas of 30 Jun 20213.62k0.02%
More ▼
Data from 31 Dec 2021 - 31 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.